Asciminib Provides Durable Responses and a Favorable Safety Profile in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with the T315I Mutation in a Phase 1 Study

被引：0

作者：

Cortes, Jorge E. ^{[1
]}

Hughes, Timothy P. ^{[2
,3
]}

Mauro, Michael J. ^{[4
]}

Hochhaus, Andreas ^{[5
]}

Rea, Delphine ^{[6
]}

Goh, Yeow-Tee ^{[7
]}

Janssen, J. J. W. M. ^{[8
]}

Heinrich, Michael C. ^{[9
,10
]}

Talpaz, Moshe ^{[11
]}

Etienne, Gabriel ^{[12
]}

Breccia, Massimo ^{[13
]}

Deininger, Michael ^{[14
]}

Le Coutre, Philipp ^{[15
]}

Lang, Fabian ^{[16
]}

Polydoros, Fotis ^{[17
]}

Cacciatore, Silvia ^{[17
]}

Stenson, Laura ^{[18
]}

Kim, Dong-Wook ^{[19
]}

机构：

[1] Georgia Canc Ctr, Augusta, GA USA

[2] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia

[3] Univ Adelaide, Adelaide, SA, Australia

[4] Mem Sloan Kettering Canc Ctr, New York, NY USA

[5] Univ Klinikum Jena, Jena, Germany

[6] Hop St Louis, Paris, France

[7] Singapore Gen Hosp, Bukit Merah, Singapore

[8] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands

[9] Vet Affairs Portland Hlth Care Syst, Portland, OR USA

[10] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[11] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[12] Univ Bordeaux, Bordeaux, France

[13] Univ Sapienza Rome Italy, Rome, Italy

[14] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[15] Charite Univ Med Berlin, Berlin, Germany

[16] Goethe Univ Hosp, Hematol & Oncol, Frankfurt, Germany

[17] Novartis Pharma AG, Basel, Switzerland

[18] Novartis Ireland Ltd, Dublin, Ireland

[19] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Seoul, South Korea

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷

关键词：

CML; T315I; asciminib;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML-413

引用

页码：S335 / S336

页数：2